Vilin Bio Med Q2 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹77 Cr
- P/E
- 39.95
- ROE
- 7.51%
- PEG
- 2.56
- Price to sales
- 1.83
- Debt to equity
- 0.01
- 52W high / low
- ₹38.4 / ₹19.0
- Sales growth (5Y)
- 29.64%
- EBITDA margin
- 7.57%
- Net profit margin
- 4.57%
- Promoter holding
- 56.65%
- Sales (last year)
- ₹42 Cr
Incorporated in 2005, Vilin Bio Med Ltd is in the business of manufacturing and selling of pharmaceutical products[1]
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Vilin Bio Med shareholding (Sep 2026)
Promoters
56.65%
unchanged QoQ
FIIs
0.13%
+0.13 pp QoQ
DIIs
—
— QoQ
Public
43.22%
−0.13 pp QoQ
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹3,142 Cr | 34.2 | |
| 2 | 40%+ | Up 2%+ | ₹489 Cr | 16.7 | |
| 3 | 40%+ | Up 0–2% | ₹234 Cr | 17.8 | |
| 4 | 40%+ | Flat | ₹18,464 Cr | 1614.0 | |
| 5 | 40%+ | Flat | ₹9,050 Cr | 34.8 | |
| 6 | 40%+ | Flat | ₹4,493 Cr | — |
Sign up free to see every company in the sector ranking and track Vilin Bio Med.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Vilin Bio Med
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Vilin Bio Med
Shareholding breakup across reporting periods.
| Jun 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters + | 90.45% | 64.52% | 64.52% | 64.09% | 63.89% | 63.89% | 63.89% | 63.65% | 59.57% | 56.65% | 56.65% |
| FIIs + | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.13% |
| Public + | 9.55% | 35.48% | 35.48% | 35.91% | 36.11% | 36.11% | 36.11% | 36.35% | 40.43% | 43.35% | 43.22% |
| No. of Shareholders | 21 | 659 | 585 | 581 | 551 | 492 | 476 | 462 | 397 | 382 | 384 |
Financials of Vilin Bio Med
Quarterly Results
Quarter-by-quarter operating performance
Financials of Vilin Bio Med
Profit & Loss
Annual income statement trend
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 16.62 | 11.54 | 11.21 | 12.31 | 15.80 | 14.81 | 42.26 | 65.20 |
| Sales growth | -30.57% | -2.86% | +9.81% | +28.35% | -6.27% | +185.35% | +226.33% | |
| Expenses + | 15.71 | 10.68 | 10.44 | 9.73 | 14.97 | 14.02 | 39.06 | 60.38 |
| Operating Profit | 0.91 | 0.86 | 0.77 | 2.58 | 0.83 | 0.79 | 3.20 | 4.82 |
| OPM % | 5.48% | 7.45% | 6.87% | 20.96% | 5.25% | 5.33% | 7.57% | 7.39% |
| Other Income + | 0.01 | 0.00 | 0.00 | 0.02 | 0.32 | 0.47 | 0.00 | 0.00 |
| Interest | 0.41 | 0.44 | 0.51 | 0.65 | 0.79 | 0.85 | 0.07 | 0.00 |
| Depreciation | 0.31 | 0.26 | 0.22 | 0.17 | 0.13 | 0.10 | 0.28 | 0.41 |
| Profit before tax | 0.20 | 0.16 | 0.04 | 1.78 | 0.23 | 0.31 | 2.85 | 4.41 |
| Tax % | 20.00% | 25.00% | 25.00% | 30.34% | 26.09% | 25.81% | 31.93% | |
| Net Profit + | 0.16 | 0.12 | 0.03 | 1.25 | 0.16 | 0.22 | 1.93 | 3.06 |
| EPS in Rs | 0.16 | 0.12 | 0.03 | 1.26 | 0.11 | 0.16 | 1.27 | 2.01 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials of Vilin Bio Med
Balance Sheet
Capital structure and asset base
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.30 | 3.30 | 3.30 | 9.95 | 13.95 | 13.95 | 15.25 | 15.25 |
| Reserves | 3.94 | 4.06 | 4.10 | 0.73 | 8.89 | 9.11 | 13.12 | 14.40 |
| Borrowings + | 4.53 | 5.52 | 5.30 | 4.93 | 6.83 | 2.57 | 0.21 | 0.04 |
| Other Liabilities + | 2.24 | 1.01 | 0.86 | 2.07 | 2.73 | 2.15 | 6.36 | 9.75 |
| Total Liabilities | 14.01 | 13.89 | 13.56 | 17.68 | 32.40 | 27.78 | 34.94 | 39.44 |
| Fixed Assets + | 2.13 | 1.87 | 1.65 | 1.51 | 1.38 | 1.28 | 2.87 | 3.05 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.57 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
| Other Assets + | 11.88 | 12.02 | 11.91 | 16.17 | 31.02 | 24.93 | 32.07 | 36.37 |
| Total Assets | 14.01 | 13.89 | 13.56 | 17.68 | 32.40 | 27.78 | 34.94 | 39.44 |
Financials of Vilin Bio Med
Cash Flows
Operating, investing and financing cash movement
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -1.46 | -1.00 | 0.21 | -1.66 | -7.42 | 0.21 | 0.70 |
| Cash from Investing Activity + | -0.02 | 0.00 | 0.00 | -0.03 | 0.32 | -1.11 | -0.30 |
| Cash from Financing Activity + | 1.51 | 0.98 | -0.22 | 1.68 | 8.87 | -5.10 | 1.01 |
| Net Cash Flow | 0.03 | -0.02 | -0.01 | 0.00 | 1.77 | -5.99 | 1.41 |
| Free Cash Flow | -1.48 | -1.00 | 0.21 | -1.69 | -7.42 | -1.36 | 0.40 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -156% | -112% | 29% | -43% | -888% | 35% | 49% |
Financials of Vilin Bio Med
Ratios
Working capital efficiency and return ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 159.66 | 241.96 | 253.64 | 166.04 | 131.22 | 210.97 | 137.85 |
| Inventory Days | 56.13 | 83.17 | 93.82 | 44.74 | 125.41 | 119.50 | 70.03 |
| Days Payable | 49.48 | 33.11 | 26.34 | 60.49 | 54.71 | 39.02 | 32.59 |
| Cash Conversion Cycle | 166.31 | 292.03 | 321.13 | 150.28 | 201.91 | 291.44 | 175.29 |
| Working Capital Days | 110.91 | 204.32 | 211.64 | 45.07 | 76.23 | 374.61 | 168.16 |
| ROCE % | 4.87% | 4.30% | 17.17% | 4.51% | 4.20% | 10.77% |
Vilin Bio Med: frequently asked questions
What is Vilin Bio Med share price today?
Vilin Bio Med last traded at ₹50.55, with a market capitalisation of ₹77 Cr and a P/E ratio of 40.0.
What is the promoter holding in Vilin Bio Med?
Promoters held 56.65% of Vilin Bio Med in Sep 2026 (unchanged versus Jun 2026).
How much do FIIs and DIIs hold in Vilin Bio Med?
In Sep 2026, foreign institutional investors held 0.13% and domestic institutions (including mutual funds) held — of Vilin Bio Med.
What is Vilin Bio Med's ROE and ROCE?
Vilin Bio Med's return on equity is 7.51% and its return on capital employed is 10.8%.
Does Vilin Bio Med pay a dividend?
Vilin Bio Med's dividend yield is 0% at the current price; see the Vilin Bio Med dividends page for past payouts.
Which sector does Vilin Bio Med belong to?
Vilin Bio Med is in the Pharmaceuticals & Biotechnology sector. Its peer comparison and sector ranking are on this page.
What did Vilin Bio Med's management say on the latest earnings call?
Arthneeti's analysis of the Q2 FY27 earnings call covers revenue, margins, capex and fundraising guidance from Vilin Bio Med's management.
How does Arthneeti AI analyse Vilin Bio Med?
Arthneeti reads Vilin Bio Med's earnings call transcripts and filings and scores revenue growth, margins, capex and fundraising, then ranks the company against its sector.
Continue your research
What Vilin Bio Med's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem
